Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings

Published:2023-09-23 Issue:2 Volume:56 Page:483-497
ISSN:1573-2584
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Xiaoqin Zhang,Zhouqi Lu,Huan Pan,Xinyi Feng,Bin Shen,Jiming Wu,Shihui Liu,Bangwei Zhou,Jing Jin,Yi He,Jinlai Gao^ORCID

Funder

National Natural Science Foundation of China

Science and Technology Bureau of Jiaxing

Basic Public Welfare Research Program of Zhejiang Province

Jiaxing Medical Key Subject Funding of Zhejiang Province

the Jiaxing Key Laboratory of Precise Diagnosis and Treatment of Urological Tumor

Jiaxing Innovation Leading Program for Elite Talents

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

https://link.springer.com/content/pdf/10.1007/s11255-023-03796-7.pdf

Reference43 articles.

1. Black PC, Sridhar S (2017) New research in bladder cancer, ASCO-GU 2017. Can Urol Assoc J 11:S160–S162. https://doi.org/10.5489/cuaj.4606

2. Luo H, Xu C, Liu Z et al (2019) Neural differentiation of bone marrow mesenchymal stem cells with human brain-derived neurotrophic factor gene-modified in functionalized self-assembling peptide hydrogel in vitro. J Cell Biochem 120:2828–2835. https://doi.org/10.1002/jcb.26408

3. Arab S, Hadjati J (2019) Adenosine blockage in tumor microenvironment and improvement of cancer immunotherapy. Immune Netw 19:e23. https://doi.org/10.4110/in.2019.19.e23

4. Wolacewicz M, Hrynkiewicz R, Grywalska E et al (2020) Immunotherapy in bladder cancer: current methods and future perspectives. Cancers (Basel). https://doi.org/10.3390/cancers12051181

5. Londono MC, Reig M, Group RM (2020) Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors. Cancers (Basel). https://doi.org/10.3390/cancers12113446

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3